Variety first reported last week that Robin Wright is also boarding the movie directed by “Sicario” helmer Denis Villeneuve. The untitled film hits theaters on Jan. 12, 2018.
Sony Pictures Releasing International will distribute the film in all overseas territories. Alcon has a longstanding domestic output agreement with Warner Bros.
The screenplays, penned by Hampton Fancher (co-writer of the original) and Michael Green, and based on a story by Fancher and Ridley Scott, continues several decades after the conclusion of the 1982 original — which was set in a dystopian 2019 Los Angeles.
The original film, based on the 1968 Philip K. Dick novel “Do Androids Dream of Electric Sheep?,” starred Ford as an ex-police officer tracking down escaped genetically engineered replicants who return to Earth illegally in order to extend their four-year life spans. In 1993, the film was selected for preservation in the U.S. National Film Registry by the Library of Congress.
Principal photography on the sequel is scheduled to begin in July, with cinematographer Roger Deakins reuniting with Villeneuve on the project. Alcon Entertainment acquired the film, television and ancillary franchise rights in 2011 from the late Bud Yorkin and Cynthia Sikes Yorkin to produce prequels and sequels to the iconic science fiction thriller. Cynthia Sikes Yorkin will produce along with Alcon co-chiefs Broderick Johnson and Andrew Kosove. Bud Yorkin will receive producer credit.
Scott will serve as executive producer. Frank Giustra and Tim Gamble, CEOs of Thunderbird Films, will also serve as executive producers along with Bill Carraro.
Bautista recently appeared in Marvel Studios’ blockbuster hit “Guardians of the Galaxy” and the newest installment of the James Bond franchise, “Spectre.” His upcoming projects include Lionsgate’s action film “Marauders,” starring Bruce Willis and Adrian Grenier. He will reprise his role as Drax the Destroyer in “Guardians of the Galaxy Vol. 2” alongside Chris Pratt and Zoe Saldana, due out next year. He is repped by Gersh and DMBV.